{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:17:48Z","timestamp":1761513468622,"version":"build-2065373602"},"reference-count":18,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,11,7]],"date-time":"2013-11-07T00:00:00Z","timestamp":1383782400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.clbc.2013.10.011","type":"journal-article","created":{"date-parts":[[2013,10,27]],"date-time":"2013-10-27T17:45:43Z","timestamp":1382895943000},"page":"85-93","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Multicenter Experience of Nonpegylated Liposomal Doxorubicin Use in the Management of Metastatic Breast Cancer"],"prefix":"10.1016","volume":"14","author":[{"given":"Carlo","family":"Palmieri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivek","family":"Misra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Januszewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hosney","family":"Yosef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Ashford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Keary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neville","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"suppl 6","key":"10.1016\/j.clbc.2013.10.011_bib1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1634\/theoncologist.7-suppl_6-4","article-title":"Treatment for anthracycline-pretreated metastatic breast cancer","volume":"7","author":"O'Shaughnessy","year":"2002","journal-title":"Oncologist"},{"key":"10.1016\/j.clbc.2013.10.011_bib2","unstructured":"National Institute for Health and Care Excellence. CG81: Advanced Breast Cancer: Diagnosis and Treatment. 2009. Available at: http:\/\/publications.nice.org.uk\/advanced-breast-cancer-cg81. Accessed: November\u00a02012."},{"key":"10.1016\/j.clbc.2013.10.011_bib3","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","article-title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials","volume":"365","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.clbc.2013.10.011_bib4","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1200\/JCO.1998.16.10.3439","article-title":"Cytotoxic and hormonal treatment for metastatic breast cancer: a systemic review of published randomised trials involving 31,510 women","volume":"16","author":"Fossati","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2013.10.011_bib5","first-page":"1392","article-title":"Chemotherapy with and without anthracycline (in reply)","volume":"18","author":"Fossati","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2013.10.011_bib6","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nrclinonc.2010.122","article-title":"Rechallenging with anthracyclines and taxanes in metastatic breast cancer","volume":"7","author":"Palmieri","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.clbc.2013.10.011_bib7","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.clon.2011.10.004","article-title":"UK guidance document: treatment of\u00a0metastatic breast cancer","volume":"24","author":"Coleman","year":"2012","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.clbc.2013.10.011_bib8","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1093\/annonc\/mdp261","article-title":"Third consensus on medical treatment of metastatic breast cancer","volume":"20","author":"Beslija","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2013.10.011_bib9","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1093\/annonc\/mdn728","article-title":"Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk","volume":"20","author":"Barret-Lee","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2013.10.011_bib10","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1200\/JCO.2001.19.5.1444","article-title":"Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer","volume":"19","author":"Batist","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2013.10.011_bib11","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1093\/annonc\/mdh393","article-title":"Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer","volume":"15","author":"Chan","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2013.10.011_bib12","first-page":"CD005006","article-title":"Different anthracycline derivates for reducing cardiotoxicity in cancer patients","volume":"5","author":"van Dalen","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clbc.2013.10.011_bib13","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/00001813-200606000-00014","volume":"17","author":"Batist","year":"2006","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.clbc.2013.10.011_bib14","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/cncr.10201","article-title":"Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma","volume":"94","author":"Harris","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.clbc.2013.10.011_bib15","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) and Common Toxicity Criteria (CTC). Available at: http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_40. Accessed: November\u00a02012."},{"key":"10.1016\/j.clbc.2013.10.011_bib16","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S0140-6736(11)61625-5","article-title":"Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials","volume":"379","author":"Peto","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.clbc.2013.10.011_bib17","doi-asserted-by":"crossref","first-page":"5664","DOI":"10.1200\/JCO.2006.07.3916","article-title":"Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial","volume":"24","author":"Roch\u00e9","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2013.10.011_bib18","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/S0140-6736(09)60740-6","article-title":"Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial","volume":"373","author":"Ellis","year":"2009","journal-title":"Lancet"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820913002486?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820913002486?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:13:11Z","timestamp":1761513191000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820913002486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S1526820913002486"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2013.10.011","relation":{},"ISSN":["1526-8209"],"issn-type":[{"type":"print","value":"1526-8209"}],"subject":[],"published":{"date-parts":[[2014,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multicenter Experience of Nonpegylated Liposomal Doxorubicin Use in the Management of Metastatic Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2013.10.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}